AR059265A1 - Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1) - Google Patents

Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1)

Info

Publication number
AR059265A1
AR059265A1 ARP070100412A ARP070100412A AR059265A1 AR 059265 A1 AR059265 A1 AR 059265A1 AR P070100412 A ARP070100412 A AR P070100412A AR P070100412 A ARP070100412 A AR P070100412A AR 059265 A1 AR059265 A1 AR 059265A1
Authority
AR
Argentina
Prior art keywords
receiver1
vaniloid
espiro
inhibitory activity
compounds condensed
Prior art date
Application number
ARP070100412A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059265(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR059265A1 publication Critical patent/AR059265A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto que tiene la formula (1) :donde R1 y R2 son independientemente halo o haloalquilo C1-3, X es etenilo o etinilo,o una sal del mismo, con la condicion de que no sea 1'-[(2E)-3-(3,4-diclorofenil)prop-2-en-1-il]-2H,5H- espiro[imidazolidin-4,3'-indol]-2,2',5( 1 'H)-triona.
ARP070100412A 2006-02-07 2007-01-31 Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1) AR059265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07

Publications (1)

Publication Number Publication Date
AR059265A1 true AR059265A1 (es) 2008-03-19

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100412A AR059265A1 (es) 2006-02-07 2007-01-31 Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1)

Country Status (21)

Country Link
US (2) US20070185179A1 (es)
EP (1) EP2013215A4 (es)
JP (1) JP2009526043A (es)
KR (1) KR20080094906A (es)
CN (1) CN101415711A (es)
AR (1) AR059265A1 (es)
AU (1) AU2007212786B2 (es)
BR (1) BRPI0707423A2 (es)
CA (1) CA2641632A1 (es)
CL (1) CL2009000523A1 (es)
IL (1) IL192890A0 (es)
NO (1) NO20083547L (es)
NZ (1) NZ571070A (es)
RU (1) RU2421457C2 (es)
SA (1) SA07280027B1 (es)
SG (1) SG169387A1 (es)
TW (1) TW200801011A (es)
UA (1) UA93226C2 (es)
UY (1) UY30132A1 (es)
WO (1) WO2007091947A2 (es)
ZA (1) ZA200806407B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921576B2 (en) 2011-10-19 2014-12-30 Kowa Company, Ltd. Spiroindoline compound, and medicinal agent comprising same
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
ZA806623B (en) * 1979-11-13 1981-12-30 Ici Ltd Substituted indoline-2-one derivatives
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
EP1426375A3 (en) * 1999-07-21 2004-12-15 AstraZeneca AB Analgesic spiroindole derivatives
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
RU2333198C2 (ru) 2003-06-12 2008-09-10 Астеллас Фарма Инк. Производные бензамида или фармацевтически приемлемые соли указанного производного, фармацевтическая композиция на их основе и применение
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
JP2008508190A (ja) 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
US20090076049A1 (en) 2006-02-07 2009-03-19 Astrazeneca Ab Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1

Also Published As

Publication number Publication date
EP2013215A4 (en) 2010-09-08
IL192890A0 (en) 2009-02-11
RU2008131905A (ru) 2010-03-20
CN101415711A (zh) 2009-04-22
NZ571070A (en) 2011-07-29
SA07280027B1 (ar) 2010-11-22
TW200801011A (en) 2008-01-01
KR20080094906A (ko) 2008-10-27
NO20083547L (no) 2008-11-05
SG169387A1 (en) 2011-03-30
JP2009526043A (ja) 2009-07-16
WO2007091947A2 (en) 2007-08-16
EP2013215A2 (en) 2009-01-14
UY30132A1 (es) 2009-07-17
US7868181B2 (en) 2011-01-11
AU2007212786A8 (en) 2010-05-06
WO2007091947A8 (en) 2008-08-07
CL2009000523A1 (es) 2009-07-17
CA2641632A1 (en) 2007-08-16
AU2007212786A1 (en) 2007-08-16
AU2007212786B2 (en) 2011-06-02
WO2007091947A3 (en) 2007-10-04
US20070185179A1 (en) 2007-08-09
RU2421457C2 (ru) 2011-06-20
ZA200806407B (en) 2009-04-29
US20090137650A1 (en) 2009-05-28
UA93226C2 (en) 2011-01-25
BRPI0707423A2 (pt) 2011-05-03

Similar Documents

Publication Publication Date Title
WO2009077857A3 (en) Trail variants for treating cancer
RS52843B (en) THE NEW IS THE HYDROGEN SULPHATE
FR2933372B1 (fr) Navire dont la poupe est equipee d'un tel dispositif de deflection de flux d'eau
TW200730486A (en) Organic sulfur compounds and use thereof
MA29686B1 (fr) Sels de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
FR2926118B1 (fr) Bride en composite avec partie d'usinage.
IL215027A0 (en) ANTI-zB7R1 ANTIBODY
DE602006018447D1 (de) Substituierte indolverbindungen mit nos-hemmender aktivität
DE602007003636D1 (de) Kombination aus einem Strukturblock und einem daran angebrachten Verblendungselement
EA201101669A1 (ru) Новая соль базедоксифена
TW200627740A (en) Earthquake-safe server-rack
GB0902845D0 (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
UY30009A1 (es) Compuestos benzoilpirazol y herbicidas que los contienen
WO2007030761A3 (en) Acyclic 1,4-diamines and uses thereof
MX2009001740A (es) Ensamble de barra de sujecion para regadera y similares.
DE602005009417D1 (de) Kühlschrank ausgestattet mit einer Einheit zur Herstellung von kohlensäurehaltigem Wasser
DK1733607T3 (da) Skrå transportör til en mejetærsker
PL2131693T3 (pl) System ustalający
AR059265A1 (es) Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1)
ECSP10010491A (es) Composiciones fungicidas con 3'-bromo-2,3,4,6'-tetrametoxi-2',6-dimetilbenzofenona
CL2008002704A1 (es) Composicion herbicida que comprende un compuesto derivado de 1,4-dihidro-2h-piridazin-3-ona.
NO20074064L (no) Anropsvarsel styrt av anropets opprinnelsessystem
FI20060317L (fi) Vaellussauva, jossa on käsihihna
RU2006107361A (ru) Средство, обладающее гематопротекторным действием
PL1865766T3 (pl) Gniazda dla niosek

Legal Events

Date Code Title Description
FA Abandonment or withdrawal